# BioApp Phase 3R

Purpose: resolve Phase 3 review items for the frozen CTA-defined Immune cells endpoint without running mapping or generating biological application results.

## Inputs

- Phase 2C frozen endpoint: `visualizations/bioapp_phase2c_endpoint_freeze_with_validated_cta_to_spot_mapping`
- Phase 3 reference audit: `visualizations/bioapp_phase3_reference_audit_and_formal_baseline_feasibility_for_cta_endpoint`
- Explicit Rscript: `E:\R\R-4.5.1\bin\x64\Rscript.exe`
- ST object source: `visualizations/bioapp_phase2br2_explicit_rscript_cta_align_locale_safe_dry_run/_ascii_runtime/ST_data.RData`
- Reference directory: `data/processed/cytospace_fig2d_tme/cytospace_fig2d_tme_brca_her2_ffpe/stage1_preprocess/exported`

## Main Checks

- ST expression full endpoint coverage: `True`
- Gene overlap exact count: `2000`
- CytoSPACE manifest generated: `True`
- Control strategy resolved: `True`

## Interpretation Boundary

This phase is input harmonization and control-design review only. It does not run CytoSPACE, SVTuner, Stage4, contradiction analysis, or prevention analysis.

## Decision

`PASS`

## Next

BioApp Phase 4 — formal CytoSPACE baseline execution against frozen CTA Immune endpoint
